- Home
- MBRX vs EQS Comparison
MBRX vs EQS Comparison
Compare MBRX & EQS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBRX | EQS |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 25.8M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | MBRX | EQS |
|---|---|---|
| Price | $7.24 | $1.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $125.00 | N/A |
| AVG Volume (30 Days) | ★ 105.9K | 5.1K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,377,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.11 |
| 52 Week Low | $6.01 | $0.74 |
| 52 Week High | $91.25 | $2.49 |
Technical Indicators
Market Signals| Indicator | MBRX | EQS |
|---|---|---|
| Relative Strength Index (RSI) | 89.96 | 45.22 |
| Support Level | $0.26 | $1.77 |
| Resistance Level | $7.75 | $1.90 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | 0.83 | -0.00 |
| Stochastic Oscillator | 93.19 | 31.43 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.